Achilles Therapeutics rises on clinical manufacturing expansion in U.S., UK

Achilles Therapeutics

12/04/2022 12:52

** U.S.-listed shares of biopharma co  ACHL.O  rise ~21% to
$3.37 before the bell
    ** ACHL says it has received a license from Britain's
medical regulator for the co's manufacturing facility in
Stevenage, UK  urn:newsml:reuters.com:*:nGNX8v9jHg
    ** Co says also entered into a partnership with
Pennsylvania-based Center for Breakthrough Medicines (CBM) for
the manufacturing of its T cell product candidates known as cNet
    ** ACHL says Stevenage manufacturing site expected to have
an initial annual capacity of 200 cNeT doses at peak production
    ** Says Pennsylvania manufacturing facility to be operated
by CBM to have an initial annual capacity of 150-200 cNet doses
at peak production
    ** Up to Monday's close, ACHL down ~44% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))